364 related articles for article (PubMed ID: 36205806)
1. Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD; Baehring JM
Curr Treat Options Oncol; 2022 Nov; 23(11):1548-1565. PubMed ID: 36205806
[TBL] [Abstract][Full Text] [Related]
2. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
Nagane M
Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
4. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
Yu J; Du H; Ye X; Zhang L; Xiao H
Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Chen YB; Batchelor T; Li S; Hochberg E; Brezina M; Jones S; Del Rio C; Curtis M; Ballen KK; Barnes J; Chi AS; Dietrich J; Driscoll J; Gertsner ER; Hochberg F; LaCasce AS; McAfee SL; Spitzer TR; Nayak L; Armand P
Cancer; 2015 Jan; 121(2):226-33. PubMed ID: 25204639
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G;
Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696
[TBL] [Abstract][Full Text] [Related]
7. Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma.
Holdhoff M; Mrugala MM; Grommes C; Kaley TJ; Swinnen LJ; Perez-Heydrich C; Nayak L
J Natl Compr Canc Netw; 2020 Nov; 18(11):1571-1578. PubMed ID: 33152700
[TBL] [Abstract][Full Text] [Related]
8. Consolidation Therapy in Primary Central Nervous System Lymphoma.
Kim P; Omuro A
Curr Treat Options Oncol; 2020 Jul; 21(9):74. PubMed ID: 32725379
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
Reni M; Ferreri AJ
Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691
[TBL] [Abstract][Full Text] [Related]
10. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Omuro A; Correa DD; DeAngelis LM; Moskowitz CH; Matasar MJ; Kaley TJ; Gavrilovic IT; Nolan C; Pentsova E; Grommes CC; Panageas KS; Baser RE; Faivre G; Abrey LE; Sauter CS
Blood; 2015 Feb; 125(9):1403-10. PubMed ID: 25568347
[TBL] [Abstract][Full Text] [Related]
11. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
[TBL] [Abstract][Full Text] [Related]
12. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G
BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
[TBL] [Abstract][Full Text] [Related]
16. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Pfreundschuh M; Cabras G; Angrilli F; Ponzoni M; Deckert M; Politi LS; Finke J; Reni M; Cavalli F; Zucca E; Illerhaus G;
Lancet Haematol; 2017 Nov; 4(11):e510-e523. PubMed ID: 29054815
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
19. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
[TBL] [Abstract][Full Text] [Related]
20. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]